*Some patients in the SCAAR study were treated for either Left Main, CTO or multi-vessel disease but did not show statistical significance. The safety and efficacy of the SYNERGY BP Stent for those uses has not been established. A total of 7,886 of Synergy stents and 64,429 other n-DES (BioMatrix, N51,953; Orsiro, N54,946; Promus Element Plus, N5 2,543; Promus Premier, N5 20,414; Xience Xpedition, N5 7,971, Resolute/Resolute Integrity, N519,021; Ultimaster, N51,156; Resolute Onyx, N56,425) were implanted in 42,357 procedures.
In addition, a single-arm study of SYNERGY BP Stent reported 0% stent thrombosis and 1.2% target vessel revascularization in a leading complex PCI center in Belfast, Ireland at 1-year.2
Retrospective Analysis, August 2013 – February 20162*
We are continuing to pursue clinical evidence of patients in real-world studies through our Investigator Sponsored Research program. Learn more about our Clinical Trial Program